Log in
3D polyHIPE scaffold materials and synthetic retinoids developed at Durham University for applications in cell biology have been commercialized by Reinnervate, a Durham spin-out company, using a patent/licensing strategy. Reinnervate has raised £8m venture capital investment and has employed an average of 12 FTE staff since 2008, peaking at 27 in 2012. Polystyrene-based highly porous polyHIPE materials which act as 3D in vitro cell culture scaffolds were launched under the Alvetex® brand in November 2010 and a retinoid derivative, designed to control cellular development including stem cell differentiation down neural pathways, was launched as ec23®. The products have won several awards and Alvetex® was voted one of "The Scientist" magazine's top 10 Life Science Innovations of 2010.
Fundamental to effective treatment of diabetes is the understanding of complex mechanisms regulating the function and demise of insulin-secreting pancreatic beta-cells. Inherent limitations relating to pancreatic beta-cell supply coupled with short functional life in culture prompted the challenge to establish model clonal human beta-cells. Ulster exploited an innovative approach to first establish clonal rodent beta-cells. Further development of our novel technology resulted in the generation, patent protection, and commercialisation of world-first electrofusion-derived functional human beta-cells. Our unique and valuable beta-cell lines have been licensed to multi-national pharmaceutical companies for diabetes drug development and further commercialised by sales through ECACC (now Public Health England) to directly impact on both bio-industry and the international research community by providing a limitless supply of high quality model beta-cells for translational research and diabetes drug development.
Impact on commerce: Five stem cell culture products derived from UoE research have been brought to a global market since 2009 through the US based company StemCells Inc. StemCells Inc strategically acquired Stem Cell Sciences plc (SCS), with its licensed portfolio of UoE patents, to position themselves as a world leader in cell-based medicine. This enabled them to develop media and reagent tools in order to pursue nearer-term commercial opportunities. These products include the gold standard media for embryonic stem cell culture, iSTEM.
Beneficiaries: Commercial companies and users of the stem cell culture products.
Significance and Reach: iSTEM is the gold standard media used worldwide by researchers for maintaining mouse ES cells in their basal, non-differentiated state. Products are sold worldwide through global life sciences companies.
Attribution: All research was carried out at UoE between 1994 and 2006 (published up to 2008), led by Prof Austin Smith. Collaboration with Prof Philip Cohen, University of Dundee, on one paper (2008).
Two books and review/research articles in Italian have disseminated the findings from the underpinning research on creating false autobiographical memories and the dangers of inadequate interviewing techniques. This work has critically increased awareness in the Italian legal system amongst both barristers and judges, to the point of shaping the practice of interviewing witnesses in that country. It has also informed all verdicts on child sexual abuse by the Supreme Court of Cassation.
The Fault Dynamics Research Group (FDRG) have designed and executed analogue experiments to replicate the 3D/4D geometry of oil and gas exploration targets. The main beneficiaries are the international petroleum industry. The research is "pivotal to British Petroleum's subsurface developments" (R. Humphries BP 2012) in determining the number of multi-million pound wells required to access reserves. FDRG models "changed the way seismic data (was) interpreted" (Chief Scientist, Geoscience Australia 2012) in particular in the NW Australian frontier with "BP Exploration (Alpha)....work program(s) of $600 million" (Chief Scientist, Geoscience Australia 2012).
Pioneering research at the University of Chichester lead by Professor Harris provided in 2006 first evidence on the effectiveness of beta-alanine supplementation in augmenting carnosine content in human skeletal muscle. Subsequent studies demonstrated the performance-enhancing effect of beta-alanine supplementation, particularly in high-intensity exercise. The research was exploited by a US company through a number of worldwide patents based on Harris' work achieving sales and license revenues of $4.8M in 2013 fiscal year alone. Beta-alanine supplementation has emerged as a legal means to enhance performance taken up at amateur and elite level sport worldwide; it is having global impact on the sports nutrition industry.
Impact on society, culture and creativity; health and welfare; practitioners: Extensive public engagement with a broad target audience has increased understanding of the hopes and hypes generated by stem cell research at UoE and elsewhere, and has provided resources for practitioners to deliver high-quality public engagement and science education.
Beneficiaries: Educators, teacher trainers, science communicators, journalists; patients; students; officials in the European Commission, the European Parliament and by extension constituents.
Significance and Reach: This programme has promoted informed decision-making among non-specialists and public acceptance of stem cell-based research and future therapies in Europe (compared for instance to the USA). The project is focused on Europe, but participation is world-wide. 767,000 unique visitors have accessed the www.eurostemcell.org website. The educational tools have been used by 11,000 pupils, and engaged 20,100 participants at festivals and science centres. More than 740,000 individuals world-wide have viewed the films (>240,000 confirmed online, film showings and DVD; estimated >500,000 TV audience).
Attribution: The programme reflects a range of stem cell research, substantially based on underpinning research carried out at UoE led by Professors Austin Smith and Ian Chambers. The outreach programme is led by Professor Clare Blackburn. Leadership, management, content identification, content format, editorial input, and evaluation of the outreach programme are all led at the University of Edinburgh.
This case study concerns the impact of Plymouth University research relating to farmed fish diets, which led to changes to EU legislation with respect to two types of ingredients: animal proteins and probiotics. The impact of the reintroduction of certain animal proteins in farmed fish feeds (previously banned to protect human health) and to the authorization of a probiotic as a feed additive, involved industry investment in research, have reduced the environmental impact of farmed fishing, improved competitiveness, enhanced yield and quality and improved fish health and survival.
Work by University of Stirling staff has contributed directly to improved wildlife resource management in the Central African region. Innovative research into the status and trends of key wildlife populations, ecological impacts, resource harvests and trade, drivers of resource use and assessing management success have contributed directly to new thinking on the issue, revisions of laws and policy and to success in attracting foreign aid for management issues. Stirling staff members now advise the Government of Gabon on resource management policies, National Park management and biodiversity issues.
Research on stem cells has led to an explosion of interest in the field of regenerative medicine, with the potential for new clinical interventions and treatments. Pioneering research in Sheffield led to the founding of a spin-out company, Axordia, in 2001, focussed on the applications of human embryonic stem cells (hESC) in medicine. Several hESC lines (including SHEF-1) were generated in Sheffield by Axordia, which was sold to Intercytex in 2008 for £1.68M. These Sheffield-derived hESC lines were then sold on to a major pharmaceutical company, Pfizer, for £0.75M in 2009. As a result, a clinical grade derivative of SHEF-1 has been developed and approved for clinical trials for treating age-related macular degeneration (AMD). In addition, Sheffield research has led to the licensing and sales of key hESC marker antibodies for stem-cell quality control. Finally, Sheffield researchers have informed emerging regulatory guidelines about the safety of hESC regenerative medicine applications by authoring reports and providing evidence to a Parliamentary committee. The case study has significant impact on commerce, health and welfare and public policy.